M. Villalona

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

G. Rosner, J. Byrd, M. Ratain, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

E K Rowinsky, D. V. Von Hoff, E. Rowinsky, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer

Yan Tang, Weiqiang Zhao, Yan Tang, 2012, Journal of oncology.

Phase 1 study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy

M. Ratain, A. Venook, D. Hollis, 2001 .

Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library.

Lisheng Wang, R. Briesewitz, Xiche Hu, 2011, ACS combinatorial science.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.